Compositions and methods for treating retinal degradation
The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor.
1. A method for treating rheumatoid arthritis, comprising:
administering an effective amount of a composition to a subject in need thereof, wherein the composition comprises a pharmaceutically acceptable carrier and a compound selected from:
(i) a compound having the structure of
or a pharmaceutically acceptable salt thereof;
(ii) a compound having the structure of
or a pharmaceutically acceptable salt thereof;
(iii) stavudine (d4T);
(iv) azidothymidine (AZT);
(v) abacavir (ABC); and
(vi) a combination thereof.
2. The method of claim 1 , comprising inhibiting inflammasome activation by Alu RNA associated with a cell.
3. The method of claim 1 , comprising reducing ATP-induced permeability of a cell.
4. The method of claim 1 , comprising reducing an amount of mitochondrial reactive oxygen species in a cell.
5. The method of claim 2 , wherein the inflammasome is selected from an NLRP3 inflammasome, an IL-1beta inflammasome, and a combination thereof.
6. A method for treating diabetes, comprising:
administering an effective amount of a composition to a subject in need thereof, wherein the composition comprises a pharmaceutically acceptable carrier and a compound selected from:
(i) a compound having the structure of
or a pharmaceutically acceptable salt thereof;
(ii) a compound having the structure of
or a pharmaceutically acceptable salt thereof;
(iii) stavudine (d4T);
(iv) lamivudine (3TC);
(v) cordycepin;
(vi) azidothymidine (AZT);
(vii) abacavir (ABC); and
(viii) a combination thereof.
7. The method of claim 6 , comprising inhibiting inflammasome activation by Alu RNA associated with a cell.
8. The method of claim 7 , wherein the inflammasome is selected from an NLRP3 inflammasome, an IL-1beta inflammasome, and a combination thereof.
9. The method of claim 6 , comprising reducing ATP-induced permeability of a cell.
10. The method of claim 6 , comprising reducing an amount of mitochondrial reactive oxygen species in a cell.
11. The method of claim 6 , wherein the diabetes is type 2 diabetes.
12. The method of claim 1 , wherein the compound is selected from (i), (iii), (iv), and (v).
13. The method of claim 1 , wherein the compound is selected from (i) and (ii).
14. The method of claim 1 , wherein the compound is (i).